Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amphastar Pharma (NQ: AMPH ) 50.59 -0.14 (-0.28%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amphastar Pharma < Previous 1 2 3 4 5 6 7 Next > Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade October 15, 2024 Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. Via Investor's Business Daily JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability September 06, 2024 JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. Via Benzinga Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference August 28, 2024 Via ACCESSWIRE AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024 August 07, 2024 AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 August 07, 2024 Via ACCESSWIRE Why the growth investor may take a look at NASDAQ:AMPH. June 05, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article. Via Chartmill Exploring NASDAQ:AMPH's growth characteristics. May 15, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations Via Chartmill Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 May 08, 2024 Via ACCESSWIRE NASDAQ:AMPH, an undervalued stock with good fundamentals. March 12, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying. Via Chartmill Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024 July 31, 2024 Via ACCESSWIRE 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts June 18, 2024 These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each Via MarketBeat Topics ETFs Economy Exposures Interest Rates Amphastar Announces Additional $50 Million Increase to its Share Buyback Program June 04, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference June 03, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023 February 28, 2024 Via ACCESSWIRE Delving into NASDAQ:AMPH's Growth Prospects. February 28, 2024 Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? Via Chartmill Earnings Outlook For Amphastar Pharma February 27, 2024 Via Benzinga Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol May 22, 2024 Via ACCESSWIRE Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade May 16, 2024 The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference May 09, 2024 Via ACCESSWIRE AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 May 08, 2024 AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca May 01, 2024 The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Is NASDAQ:AMPH a Fit for Growth Investing Strategies? February 14, 2024 Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? Via Chartmill Is NASDAQ:AMPH a Fit for Growth Investing Strategies? February 07, 2024 Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. Via Chartmill Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024 April 30, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies April 10, 2024 Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... Via Benzinga Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference April 01, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference March 06, 2024 Via ACCESSWIRE Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024 February 20, 2024 Via ACCESSWIRE CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ February 13, 2024 CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
